Laboratories associated with small hospitals often have limited expertise, personnel, and equipment to rapidly identify rare and emerging infectious diseases. We describe the successful use of the FilmArray system for rapid detection of Ebola virus directly from clinical samples in 6 out of 83 tested subjects in a small health care center in Sierra Leone.
Clinical diagnostic laboratories associated with small health care facilities often lack the personnel, resources, and expertise for rapid identification of rare or emerging infectious diseases, relying instead on reference diagnostic laboratories for specialized tests. In developing countries, especially in outbreak situations, this strategy can cause significant delays in isolation and treatment of infected (and potentially highly infectious) individuals. The ability for a small clinical lab to identify persons infected with a sporadic or epidemic pathogen, while maintaining a low logistical burden, would be of great advantage in remote or resource-limited regions, where patients with high-impact pathogens are encountered infrequently. This study describes the deployment and use of the FilmArray multiplex PCR instrument for detection of Zaire ebolavirus in patients and health care workers (HCWs) suspected to have Ebola virus disease (EVD) in Mercy Hospital in Bo, Sierra Leone.Study. Mercy Hospital is a small private hospital in Bo, Sierra Leone, that refers about 2,000 patients per year to its own clinical laboratory for testing (1). Prior to the 2014 EVD outbreak, Mercy Hospital Research Laboratory (MHRL) initiated a communitybased research study that included use of BioFire's FilmArray instrument and the associated BioThreat (BT) Panel in a "researchonly" (rather than diagnostic) capacity. The research protocol was approved by the Sierra Leone Ethics and Scientific Review Committee (SLESRC) and by the institutional review boards of Njala University, George Mason University, and the U.S. Naval Research Laboratory. Infectious agent detection using the BT Panel is based on nested PCR (coupled with reverse transcription for RNA viruses) and melting curve analysis for amplicon discrimination (2). The BT Panel simultaneously tests for 16 pathogens, including Zaire ebolavirus; analysis is complete within 60 min, and the system yields a dichotomous detected/not detected result for each of the 16 targets tested. Given that this test requires only simple handling steps-dilution of whole blood and loading of the specimen into the test pouch-and an identical assay (the BioThreat-E test, limited to reporting results for Zaire ebolavirus) has recently received emergency use authorization (EUA) for use in the current outbreak in West Africa (3), we sought to detect the occurrence of Zaire ebolavirus among persons referred to the MHRL facilities for diagnostic testing and to assess the system's utility under conditions of sporadic use. No medical decisions were based on the BT Panel testing results.